The St Vincent’s Hospital Heart Lung Transplant Unit has carried out the world’s first distant procurement of hearts donated after circulatory death (DCD). These hearts were subsequently resuscitated and then successfully transplanted into patients with end-stage heart failure.
Transplant Units until now have relied solely on donor hearts from brain-dead patients whose hearts are still beating. The use of DCD hearts, where the heart is no longer beating, represents a paradigm shift in organ donation and will herald a major increase in the pool of available hearts for transplantation.
St Vincent’s has recently transplanted two patients using DCD hearts both of whom have recovered extremely well. The DCD transplants were carried out following pioneering basic and translational research undertaken by the Victor Chang Cardiac Research Institute and St Vincent’s Hospital, who have jointly developed a special preservation solution that together with the use of a novel portable console to house, resuscitate and transport donor hearts; has made this milestone achievable.
The ex vivo Organ Care System (OCS – TransmedicsTM) involves the Transplant retrieval team connecting the donor heart to a sterile circuit where it is kept beating and warm thereby limiting the detrimental effects of cold ischaemia (a period where the heart is dormant without oxygen and nutrients) that occurs with the standard organ preservation mode of packing the heart on ice in an Esky. Once housed inside the portable device, the heart is reanimated, preserved and able to be functionally assessed until it is ready to be placed inside the recipient.
Coined the “Heart in a box”, for the past several months the OCS has provided the transplant surgeons greater versatility with regard to both organ preservation and resuscitation. This has enabled the St Vincent’s Transplant Unit to conduct several regular heart transplants this year through more long distance organ retrievals and most importantly, retrieval of “marginal hearts”, that is, brain death hearts previously regarded as being unsuitable for transplantation.
This portable OCS technology will help significantly in mitigating the significant disparity that remains between the increasing number of patients with end-stage heart failure on the transplant waiting list and the number of suitable donor-hearts that are available. Whilst the use of DCD organs has already made an enormous positive impact on liver, kidney and lung transplantation, it has to date not been possible to use DCD hearts. This is the first time internationally that human heart transplantation has been achieved with hearts donated following circulatory death and procured at a distance with portable organ preservation technology.
The Latest on: End-stage heart failure
[google_news title=”” keyword=”end-stage heart failure” num_posts=”10″ blurb_length=”0″ show_thumb=”left”]
via Google News
The Latest on: End-stage heart failure
- ‘Can I get a soda?’ First words from historic artificial heart recipienton July 25, 2024 at 12:55 pm
The medical team was amazed by the speed with which the patient, suffering from end-stage heart failure, recovered. As Dr William Cohn, a transplant surgeon and chief medical officer of BiVacor, said: ...
- Texas Heart Institute announces 'groundbreaking' artificial heart implantationon July 25, 2024 at 12:43 pm
The Texas Heart Institute on Thursday announced a medical milestone: The first implantation of a total artificial heart with no valves.
- Texas Heart Institute and BiVACOR achieve milestone with total artificial heart implantationon July 25, 2024 at 9:32 am
The Texas Heart Institute (THI) and BiVACOR, a clinical-stage medical device company, announced today the successful first-in-human implantation of the BiVACOR Total Artificial Heart (TAH) as part of ...
- First totally artificial heart successfully implanted in patient in Houston, Texas Heart Institute sayson July 25, 2024 at 8:04 am
The Texas Heart Institute, and Baylor College of Medicine in the Texas Medical Center," said Brad Lembcke, Baylor St. Luke's Medical Center president. "Together, we are ushering in a new era of hope ...
- Successful first-in-human implantation of the BiVACOR Total Artificial Heart by Baylor and THI doctorson July 25, 2024 at 5:01 am
The first-in-human clinical study aims to evaluate the safety and performance of the BiVACOR TAH as a bridge-to-transplant solution for patients with severe biventricular heart failure or ...
- The Texas Heart Institute implants BiVACOR® Total Artificial Hearton July 25, 2024 at 3:31 am
Utilizing advanced MAGLEV technology, our TAH brings us one step closer to providing a desperately needed option for people with end-stage heart failure who require support while waiting for a heart ...
- Patient Enrollment Commenced in Pivotal Phase 3 Trial of CardiAMP Cell Therapy for the Treatment of Ischemic Heart Failureon July 25, 2024 at 12:00 am
During heart failure progression, the heart steadily loses its ability to respond to increased metabolic demand, and mild exercise soon exceeds the heart’s ability to maintain adequate output. Towards ...
- New blood test could predict if you’ll develop cancer, heart failure and 65 other diseases 10 years before they strike’on July 23, 2024 at 3:10 am
A BLOOD test could one day predict a person’s risk of 67 diseases up to ten years before they strike, scientists say. They identified proteins in the blood that could help in the early diagnosis ...
- Heart Transplantationon July 21, 2024 at 5:00 pm
Patients begin with the diagnosis of end-stage heart disease. Adults who require cardiac transplantation usually have a primary diagnosis of end-stage coronary artery disease (44%) or ...
- Surgical Options for the Treatment of Heart Failureon July 16, 2024 at 5:01 pm
The role for CABG in patients with heart failure depends upon myocardial ... the routine last option in appropriate patients with end stage cardiomyopathy. Transplant is still limited by donor ...
via Bing News
